Journal of Clinical Lipidology

Original Article

9

Effects of morning vs evening statin administration on lipid profile: An systematic review and meta-analysis 12 02

13 🛺 Kamal Awad*, Maria-Corina Serban, Peter Penson, Dimitri P. Mikhailidis, Peter P. Toth, Steven R. Jones, Manfredi Rizzo, George Howard, Gregory Y. H. Lip, Maciej Banach, Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group

19 💀 Faculty of Medicine, Zagazig University, Egypt (Dr Awad); Student Research Unit, Zagazig University, Egypt (Dr Awad); Department of Functional Sciences, Discipline of Pathophysiology, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania (Dr Serban); School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, United Kingdom (Dr Penson); Department of Clinical Biochemistry, Royal Free Campus, University College London Medical School, University College London (UCL), London, United Kingdom (Dr Mikhailidis); Preventive 24 of Cardiology, CGH Medical Center, Sterling, IL, USA (Dr Toth); The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA (Drs Toth and Jones); Biomedical Department of Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy (Dr Rizzo); Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA (Dr Howard); University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom (Dr Lip); Department of Hypertension, Medical University of Lodz, Poland (Dr Banach); and Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz,

Poland (Dr Banach)

BACKGROUND: Evidence about the optimal time of day at which to administer statins is lacking. **KEYWORDS: OBJECTIVE:** The objective of this study is to synthesize evidence about effects of morning vs eve-Cholesterol; ning statin administration on lipid profile. LDL; METHODS: We searched PubMed, SCOPUS, Web of Science, and Embase databases (from incep-Hydroxymethylglutaryl-tion up to July 24, 2016) to identify the relevant studies. Mean differences (MDs) between the change CoA reductase inhibitors; scores in lipid parameters were pooled using a fixed-effect model. Half-life; **RESULTS:** Eleven articles with 1034 participants were eligible for the analysis. The pooled analysis Lipids comparing effects of morning vs evening administration of statins on plasma total cholesterol (TC; P = .10), high-density lipoprotein cholesterol (P = .90), and triglycerides (P = .45) was not statisti-cally significant. Low-density lipoprotein cholesterol (LDL-C) lowering was statistically greater in the evening-dose group (MD: 3.24 mg/dL, 95% CI: 1.23–5.25, P = .002). Subgroup analysis according to statin half-lives showed that evening dose of statins was significantly superior to morning dose for lowering LDL-C in case of both short and long half-life statins (MD: 9.68 mg/dL, 95% CI: 3.32-16.03, P = .003 and MD: 2.53 mg/dL, 95% CI: 0.41–4.64, P = .02, respectively) and also for TC reduction in case of short half-life statins only (P = .0005).

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

50 Q5 * Corresponding author. Faculty of Medicine, Student Research Unit,

Zagazig University, Zagazig, El-Sharkia, Egypt 44519. E-mail address: kamal225244@medicine.zu.edu.eg Submitted November 16, 2016. Accepted for publication June 2, 2017.

1933-2874/© 2017 National Lipid Association. All rights reserved. http://dx.doi.org/10.1016/j.jacl.2017.06.001

2

103

104

105

106

107

108 109

110

© 2017 National Lipid Association. All rights reserved.

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

111 Introduction112

113 Coronary heart disease is the leading cause of mortality and morbidity world wide.^{1,2} It is now unequivocal that 114 115 elevated levels of total cholesterol (TC) and low-density li-116 poprotein cholesterol (LDL-C) are major risk factors for the 117 development of atherosclerosis and coronary heart disease 118 and that lowering these values diminishes the incidence of these diseases.^{3–10} Previous meta-analyses showed that 119 for every 1.0 mmol/L (38.7 mg/dL) reduction in LDL-C, 120 121 there is a corresponding 20%-25% reduction in cardiovas-122 cular disease (CVD) mortality.¹¹

123 The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are very effective drugs for reducing the 124 elevated levels of plasma cholesterol.^{2,12} Statins reduce 125 both LDL-C and triglycerides (TGs) by up to 50% and 126 20%, respectively.^{2,13} Moreover, they increase high-127 density lipoprotein cholesterol (HDL-C) by up to 128 10%.^{14,15} It is now well established that statins are benefi-129 cial for primary and secondary prevention of CVD.^{7–10,16–20} 130 131 In a meta-analysis of 170,000 participants, which included 132 data from 26 randomized controlled trials (RCTs) with sta-133 tins, all-cause mortality was reduced by 10%, coronary ar-134 tery disease death by 20%, risk of major coronary events by 135 23%, and risk of stroke by 17% per 1 mmol/L (38.7 mg/dL) reduction in LDL-C.²¹ Statins are considered to be the stan-136 137 dard therapy for many types of dyslipidemia due to their 138 ability to inhibit the endogenous biosynthesis of cholesterol 139 and to increase the hepatic uptake of LDL-C by stimulating the expression of LDL-C receptors in the liver.^{11,12,22} This 140 141 is important because more than 75% of cholesterol found in 142 the body is synthesized endogenously and two-thirds of it is 143 synthesized in the liver alone.¹²

144 Statins are usually administrated in the evening because 145 cholesterol biosynthesis peaks during the night and also because most of them (simvastatin, pravastatin, fluvastatin, 146 and lovastatin) have short half-lives.^{12,23–25} The timing of 147 148 drug administration can alter patient compliance and adher-149 ence to the treatment.²⁶⁻²⁸ Patients treated with statins 150 often receive multiple concomitant medications and this 151 leads to more complex drug regimens, which have the potential to reduce compliance and adherence to therapy.^{29,30} 152 153 Allowing flexibility in choosing the time, at which statins 154 are administrated, according to the patient's preference, is

likely to improve patient compliance and decrease drug
discontinuation.³¹ This will enable more patients to achieve
their target lipid levels.^{32,33}

158 Therefore, we performed this systematic review and meta-analysis to synthesize evidence about the different

effects of morning and evening statin administration on lipid profiles to discover the dosing regimen, which led to the highest therapeutic efficacy.

Material and methods

CONCLUSIONS: LDL-C and TC lowering were significantly greater in the evening dose than in the

morning dose in case of short-acting statins. Besides slight but significant effect on LDL-C, the efficacy

of long-acting statins was equivalent for both regimens. Therefore, long-acting statins should be given

at a time that will best aid compliance. Short-acting statins should be given in the evening.

We followed Preferred Reporting Items for Systematic Reviews and Meta-analyses statement guidelines during the preparation of this meta-analysis (Supplementary File 1: Table S1).³⁴ This meta-analysis was registered in PROS-⁶⁶ PERO, University of York (CRD42016043480).

Search strategy

We searched PubMed, SCOPUS, Web of Science, and Embase from inception until July 24, 2016, using the following query: (atorvastatin OR fluvastatin OR lovastatin OR pitavastatin OR pravastatin OR rosuvastatin OR simvastatin OR cerivastatin OR mevinolin OR statin OR statins) AND (morning) AND (evening). Additional searches for potential trials included the references of review articles on that issue and the abstracts from selected congresses: scientific sessions of the European Society of Cardiology, the American Heart Association, American College of Cardiology, European Society of Atherosclerosis, and National Lipid Association. The wild-card term "*" was used to increase the sensitivity of the search strategy. The literature search was limited to articles published in English and to studies on humans.

After removal of duplicates by Endnote X7 (Thompson Reuter, CA), 2 independent authors (K.A. and P.P.) screened the retrieved citations in 2 steps; the first step was to screen the titles and abstracts for eligibility and the second step was to screen the full texts of the eligible abstracts according to the inclusion and exclusion criteria. Disagreement was resolved by the opinion of a third author (M.B.)

Study selection

Original studies were included if they met the
following criteria: (1) prospective or retrospective clinical
controlled studies (with randomized or nonrandomized
design); (2) comparing the effects of morning administra-
tion against evening administration of statin therapy on
one of the following lipid profile parameters: TC, LDL-C,
HDL-C, or TG; and (3) reporting sufficient information on
blood lipid levels at baseline and at the end of study in208
209

Download English Version:

https://daneshyari.com/en/article/5615238

Download Persian Version:

https://daneshyari.com/article/5615238

Daneshyari.com